Key result
OAC or antiplatelet therapy shows no benefit over no treatment for stroke in CHA2DS2-VASc 0 AF.
Why the study?
Patients with atrial fibrillation and a CHA2DS2-VASc score of 0 have a very low risk of stroke and current guidelines recommend no antithrombotic therapy, but the rate and risk of adverse events and impact of antithrombotic management in this group were investigated.
Does oral anticoagulation or antiplatelet therapy reduce stroke/thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 0?
Cohort (n=616)
No
Does oral anticoagulation or antiplatelet therapy reduce stroke/thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 0?
Relative Risk: 0.99 (95% CI 0.25–3.99)
p-value: p=0.99
In AF patients with a CHA2DS2-VASc score of 0, antithrombotic therapy does not reduce the risk of stroke or thromboembolism, supporting guidelines that recommend no antithrombotic therapy for this group.
No takes yet. Share an insight, caveat, or question.
Supports withholding antithrombotic therapy in CHA₂DS₂-VASc=0 AF; leaves open whether DOACs or updated cohorts modify net benefit.
Taillandier et al. (2012) conducted a cohort in Atrial Fibrillation (n=616). Oral anticoagulation and/or antiplatelet therapy vs. No antithrombotic treatment was evaluated on stroke/thromboembolism (RR 0.99, 95% CI 0.25-3.99, p=0.99). In AF patients with a CHA2DS2-VASc score of 0, oral anticoagulation and/or antiplatelet therapy did not reduce the risk of stroke or thromboembolism compared to no treatment (RR 0.99; 95% CI 0.25-3.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: